drugset / Trial / NCT05060588
Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
RandomizedParallel-groupTriple-blindTreatment
Summary
Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute myocardial infarction is beneficial, especially in patients combined with reduced LVEF or mild-moderate heart failure. Therefore, ACEI/ARB is a traditional treatment for patients post-infarction. Recent clinical trials have demonstrated that Sacubitril/Valsartan is more beneficial than Ramipril to patients post-PCI.Besides, Sacubitril/Valsartan is also effective for essential hypertension.This study aims to assess the effect of Sacubitril/Valsartan on short-term prognosis in hypertensive patients with acute myocardial infarction compared against Valsartan.
Timeline
- Start
- 2021-10
- Primary completion
- 2022-10
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacubitril/Valsartan | Unknown | 24 mg | — |
| Subject | Sacubitril/Valsartan | Unknown | 26 mg | — |
| Comparator | Valsartan | Small molecule | 80 mg | — |